<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11291">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959944</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1140-IM</org_study_id>
    <nct_id>NCT02959944</nct_id>
  </id_info>
  <brief_title>Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)</brief_title>
  <acronym>iNTEGRATE</acronym>
  <official_title>Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects
      with newly diagnosed moderate to severe cGVHD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate at 24 weeks</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Response will be defined by the NIH Consensus Development Project Criteria (2014)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with steroid dose reduction at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal of all immunosuppressants at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) from time of randomization until the time of death due to any cause</measure>
    <time_frame>Approximately 3 years after the first subject is randomized</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate at 48 weeks</measure>
    <time_frame>up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and prednisone versus placebo in combination with prednisone</measure>
    <time_frame>Up to 30 days after the last participating subject discontinues study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Chronic Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib in combination with prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <description>Ibrutinib capsules administered orally daily</description>
    <arm_group_label>Ibrutinib</arm_group_label>
    <other_name>IMBRUVICA®</other_name>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules administered orally daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone administered daily</description>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New onset moderate or severe cGVHD as defined by the 2014 NIH Consensus Development
             Project Criteria

          -  Need for systemic treatment with corticosteroids for cGVHD

          -  No previous systemic treatment for cGVHD (including extracorporeal photopheresis
             [ECP])

          -  May be receiving other immunosuppressants for the prophylaxis or treatment of acute
             GVHD but the doses of these medications must have been stable for at least 2 weeks
             prior to Screening

          -  Age ≥12 years old

          -  Karnofsky or Lansky (subjects &lt;16 years) performance status ≥60

        Exclusion Criteria:

          -  Received any previous systemic treatment for cGVHD

          -  Inability to begin a prednisone dose ≥0.5 mg/kg/d for the treatment of cGVHD

          -  Any uncontrolled infection or active infection requiring ongoing systemic treatment

          -  Progressive underlying malignant disease or any post-transplant lymphoproliferative
             disease

          -  Known bleeding disorders

          -  Active hepatitis C virus (HCV) or hepatitis B virus (HBV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Styles, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PCYC1140 Study Team</last_name>
    <email>1140@pcyc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet McDowell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Program</last_name>
      <phone>800-811-8480</phone>
      <email>CIP@vanderbilt.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>October 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic graft versus host disease</keyword>
  <keyword>PCYC1140</keyword>
  <keyword>PCYC1140IM</keyword>
  <keyword>1140</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>GVHD</keyword>
  <keyword>Steroid dependent</keyword>
  <keyword>refractory</keyword>
  <keyword>chronic</keyword>
  <keyword>PCI32765</keyword>
  <keyword>IMBRUVICA</keyword>
  <keyword>Pharmacyclics</keyword>
  <keyword>PCYC</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>immunology</keyword>
  <keyword>new onset graft versus host disease</keyword>
  <keyword>INTEGRATE</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
